A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
about
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsPhase I trial of vinflunine and pemetrexed in refractory solid tumors.Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro.Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy.Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.First- and second-line therapy for metastatic urothelial carcinoma of the bladderNovel agents for advanced bladder cancer.Current therapeutic strategies for invasive and metastatic bladder cancer.Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.Personalized therapy for urothelial cancer: review of the clinical evidence.Novel therapies in genitourinary cancer: an update.From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group.Novel strategies for treating relapsed/refractory urothelial carcinoma.Systemic therapy for metastatic urothelial carcinoma.Current optimal chemotherapy for advanced urothelial cancer.Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial CarcinomaCritical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.Novel anti-tubulin cytotoxic agents for breast cancer.Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experienceSystemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.Vinflunine: review of a new vinca alkaloid and its potential role in oncology.New agents for bladder cancer.Vinflunine in the treatment of advanced bladder cancer.Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.Current chemotherapeutic strategies against bladder cancer.Management of advanced bladder cancer in patients with impaired renal function.Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response.Current treatment of metastatic bladder cancer and future directions.Urothelial cancers: using biology to improve outcomes.Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.Targeting the VEGF pathway in metastatic bladder cancer.
P2860
Q28280571-E1E9CB1D-0521-4881-96F4-3D69CFD22836Q30428531-82C252BA-4910-43C7-A1E1-E526721235E9Q30964757-BE42E674-B51E-4B12-812A-9AC96317C09EQ33321973-9D9C3391-DF10-40C9-A3FD-2323105E7DDAQ33377834-8BD0F912-6380-48EB-971E-50D7AD9F9196Q33426694-A2353BA6-E387-4287-9FA4-10CFFEFF3909Q33431220-D9C53F96-5D9B-4C61-A0D5-EA16D3272CD0Q33621281-EF013576-AD35-4F44-A6AF-286C2AD8A287Q34336217-754FB517-7CC7-4EBA-BAB4-11CF7E444324Q34438928-36447535-13D9-499B-B9D8-F66AE293705CQ34541463-FCBECA47-2B6A-4BEB-B840-DFB78B4A58D2Q35076184-96051DBF-CFED-4CD4-AD99-44D706DAE81EQ35128721-3328F677-4A02-4E55-AFF2-27028FD9BE53Q35956711-01838ECA-1CDA-4D0D-B9D0-D5C974CE4F5DQ36062762-E7F8C17A-289A-4362-8D53-9675F6D5B850Q36856612-682EF9AF-464D-4EA8-B404-0A1A8D86A1A8Q36859124-12CB16D2-4E77-4D7A-9A40-1D79C62320EBQ36947812-20378FFF-F068-4796-AF99-B6593F412B09Q36995686-522B3A3F-8483-4D68-916A-E521E0C636ADQ37028356-C8446D7F-13F1-42EF-BF19-E101D4F176EFQ37038897-09A22CE0-F76A-450A-8A97-5A420115D53BQ37261102-7850DE44-6E83-43FD-9172-BA05AB4E5F72Q37284023-442EBFCC-5F9F-4E3A-89D8-DC403DCC60A0Q37323009-C878D712-8025-43B2-8AEB-18CACD2A8CBCQ37385373-E488DA96-3E11-45E1-A4BB-F1D88C1E1BA0Q37514607-F5DE455C-EEE6-4A9C-934E-0D535EB2C2ABQ37665453-AF1BD2CB-DC27-4703-A500-2F43D73C3DEBQ37763156-7C5007BA-A544-496F-9D30-1E59C488A724Q37768280-8CA7DAB0-3CE6-436E-A63E-3EB637E0F201Q37799952-80ABE270-4AD0-4234-B03B-288050E3A0A8Q37821892-742AB23A-4A9C-449D-AEC7-999C62B8701AQ37869505-2D6F05EB-88DA-4CA2-AEBB-6B74CFC42640Q37888549-54D59F56-DB7B-468D-9CCF-B83E75A07731Q37894683-7F3860C6-73EF-441E-B0D4-95B1ECF93A5EQ37959798-EC5156EF-9A05-49F9-A405-994857860FCEQ37960909-59FCC495-1FE5-4289-8E25-12C063517BD4Q37965638-B5DB9669-4418-404A-9612-BE7E31050854Q38155201-E270AB36-C6EB-41D3-B82B-7971A549733CQ38457425-90078149-282D-47C1-A1E6-DBFFE1C987E9Q38534167-431A3271-D5C0-43E8-AF41-553ABB380B15
P2860
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A phase II study of vinflunine ...... ne platinum-containing regimen
@ast
A phase II study of vinflunine ...... ne platinum-containing regimen
@en
type
label
A phase II study of vinflunine ...... ne platinum-containing regimen
@ast
A phase II study of vinflunine ...... ne platinum-containing regimen
@en
prefLabel
A phase II study of vinflunine ...... ne platinum-containing regimen
@ast
A phase II study of vinflunine ...... ne platinum-containing regimen
@en
P2093
P2860
P356
P1476
A phase II study of vinflunine ...... ne platinum-containing regimen
@en
P2093
B Longerey
C Theodore
F-M Delgado
M De Santis
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603118
P407
P577
2006-05-01T00:00:00Z